Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.11. | Aprea Therapeutics GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
07.11. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
07.11. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
23.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.10. | Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit | 3 | GlobeNewswire (USA) | ||
09.10. | APRE stock touches 52-week low at $2.22 amid market challenges | 1 | Investing.com | ||
09.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
09.10. | Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development | 1 | GlobeNewswire (USA) | ||
09.09. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
04.09. | APRE stock touches 52-week low at $3.17 amid market challenges | 1 | Investing.com | ||
28.08. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
21.08. | Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M | 1 | Seeking Alpha | ||
12.08. | APRE stock touches 52-week low at $3.22 amid market challenges | 1 | Investing.com | ||
12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 112 | GlobeNewswire (Europe) | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash... ► Artikel lesen | |
12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
21.06. | Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 | 1 | GlobeNewswire (USA) | ||
17.06. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | 137 | GlobeNewswire (Europe) | APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,500 | -15,59 % | Community-Rückblick: wO User zu Evotec Übernahmeangebot: "Als Aktionär sage ich NEIN! Viel zu wenig!" | © Foto: Christian Charisius - picture alliance/dpaDie Community um Evotec ist in Aufruhr, nachdem am 14.11. ein Übernahmeangebot seitens Halozyme Therapeutics ans Licht kam. Der Aktienkurs von Evotec... ► Artikel lesen | |
QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
BIONTECH | 108,90 | +0,28 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
DYNE THERAPEUTICS | 29,690 | -0,27 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
MODERNA | 39,575 | +0,18 % | Die Anleger von Moderna zittern vor Robert F. Kennedy, auch BioNTech gerät unter Druck, Pfizer folgt dem Beispiel und Novo Nordisk bekommt es mit immer mehr Konkurrenz zu tun | Rund zwei Monate vor dem Amtsantritt von Donald Trump nimmt dessen Kabinett langsam Formen an. Die Presse findet für die bisherigen Entscheidungen illustre Worte, sehr beliebt ist etwa das "Gruselkabinett".... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |